Moreover, in a retrospective study, for ALK–rearranged or EGFR–mutant lung cancer, Dutta et al.,12 reported that patients treated solely with TKIs achieved a 94% partial intracranial response at 3 months, whereas 58% of those receiving TKIs combined with radiation achieved this outcome. This evidence concerns the gene ALK and lung cancer.